ERYTech: H1 15 loss higher than expected. But towards a US listing and the frontline setting in ALL… What else ?

BUY, Fair Value EUR42 (+25%)
News published on September Tuesday 29, 2015
Share on

The H1 15 loss is wider than anticipated, mainly due to a faster-than-expected progression of R&D expenses. Apart from this, we note that the company is effectively planning to initiate new trials to expand its reach to the first-line in ALL. This is clearly good news as we think the company will not only expand its addressable patient population, but also benefit from a favourable basis of comparison in terms of pricing (Erwinaze cost of treatment ranging from USD100,000 to 150,000). Also, we wonder if management is not considering a standalone strategy in the US given the very limited salesforce it would need. BUY reiterated with a FV of EUR42, while keeping in mind that this number should evolve once we have more details on the company’s strategy.

For more information, please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities